(AFP, 2012-01-20)
Original: http://www.google.com/hostednews/afp/article/ALeqM5jrKtAH1a6ABJeK1s46AM4rPJOIFQ?docId=CNG.1c6dafea9831a4e285a8fd5725fe404e.81
Original: http://www.google.com/hostednews/afp/article/ALeqM5jrKtAH1a6ABJeK1s46AM4rPJOIFQ?docId=CNG.1c6dafea9831a4e285a8fd5725fe404e.81
首爾 - 韓國政府藥品監督管理局週四宣布批准世界上第一個的從其他人收集的醫藥使用幹細胞作商業銷售。
SEOUL — South Korea's government drug agency cleared the way Thursday for commercial sales of what it called the world's first approved medicine using stem cells collected from other people.
韓國食品和藥物管理局稱: 漢城Medipost開發的Cartistem將使用從新生兒臍帶血幹細胞輔助再生膝蓋軟骨.
Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns' umbilical cord blood, the Korea Food and Drug Administration said.
“Cartistem是世界上第一個批准的異體（從同一物種的不同個體採取）幹細胞的藥物，它可以提供新的治療機遇給退化性關節炎患者”,政府在一份聲明中表示.
"Cartistem is... the world's first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis," the administration said in a statement.
Medipost稱私人投資者和政府基金已自2001年以來投資270億韓元（$2380萬美元）發展 Cartistem. 此藥物可以通過手術注射到患者的膝蓋.
Medipost said 27 billion won ($23.8 million) from private investors and government funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient's knees via surgery.
聲明中稱，自去年以來(藥物)已經在美國進行臨床試驗。
Clinical trials have been under way in the United States since last year, the statement said.
韓國食品和藥物管理局稱: 漢城Medipost開發的Cartistem將使用從新生兒臍帶血幹細胞輔助再生膝蓋軟骨.
Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns' umbilical cord blood, the Korea Food and Drug Administration said.
“Cartistem是世界上第一個批准的異體（從同一物種的不同個體採取）幹細胞的藥物，它可以提供新的治療機遇給退化性關節炎患者”,政府在一份聲明中表示.
"Cartistem is... the world's first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis," the administration said in a statement.
Medipost稱私人投資者和政府基金已自2001年以來投資270億韓元（$2380萬美元）發展 Cartistem. 此藥物可以通過手術注射到患者的膝蓋.
Medipost said 27 billion won ($23.8 million) from private investors and government funds had been invested to develop Cartistem since 2001. The drug can be injected into a patient's knees via surgery.
聲明中稱，自去年以來(藥物)已經在美國進行臨床試驗。
Clinical trials have been under way in the United States since last year, the statement said.
Two of the world's top 10 drugmakers are in talks to seek a worldwide licence to make the drug, a Medipost spokesman told AFP, adding that final trials involving a large number of people would likely begin in the US in 2015.
免責聲明: 以上中文翻譯版本只供參考用途.
Disclaimer: The above Chinese translation version is for reference only.
Translated by Pat Chu on 2012-01-21
No comments:
Post a Comment